&lt;p&gt;Exosomal lncRNA ROR1-AS1 Derived from Tumor Cells Promotes Glioma Progression via Regulating miR-4686&lt;/p&gt;

Chai, Yang; Wu, Haitao; Liang, Chaozhao; You, Chun-Yue; Xie, Mingwei; Xiao, Shun-Wu

doi:10.2147/ijn.s271795

Cited by 29 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, lncRNA ROR1-AS1 promotes glioma progression by inhibiting miR-4686 (12). The expression level of NEAT1 significantly increases in glioma tissues and promoted cell migration and invasion by regulating the miR-139-5p/CDK6 pathway (13). MES-related lncRNA miR155HG binds to miR-185 to affect proliferation, cell cycle progression, and apoptosis in GBM cell lines (14).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma

et al. 2021

View full text Add to dashboard Cite

Glioma is well known as the most aggressive and prevalent primary malignant tumor in the central nervous system. Molecular subtypes and prognosis biomarkers remain a promising research area of gliomas. Notably, the aberrant expression of mesenchymal (MES) subtype related long non-coding RNAs (lncRNAs) is significantly associated with the prognosis of glioma patients. In this study, MES-related genes were obtained from The Cancer Genome Atlas (TCGA) and the Ivy Glioblastoma Atlas Project (Ivy GAP) data sets of glioma, and MES-related lncRNAs were acquired by performing co-expression analysis of these genes. Next, Cox regression analysis was used to establish a prognostic model, that integrated ten MES-related lncRNAs. Glioma patients in TCGA were divided into high-risk and low-risk groups based on the median risk score; compared with the low-risk groups, patients in the high-risk group had shorter survival times. Additionally, we measured the specificity and sensitivity of our model with the ROC curve. Univariate and multivariate Cox analyses showed that the prognostic model was an independent prognostic factor for glioma. To verify the predictive power of these candidate lncRNAs, the corresponding RNA-seq data were downloaded from the Chinese Glioma Genome Atlas (CGGA), and similar results were obtained. Next, we performed the immune cell infiltration profile of patients between two risk groups, and gene set enrichment analysis (GSEA) was performed to detect functional annotation. Finally, the protective factors DGCR10 and HAR1B, and risk factor SNHG18 were selected for functional verification. Knockdown of DGCR10 and HAR1B promoted, whereas knockdown of SNHG18 inhibited the migration and invasion of gliomas. Collectively, we successfully constructed a prognostic model based on a ten MES-related lncRNAs signature, which provides a novel target for predicting the prognosis for glioma patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…LncRNA MATN1-AS1 competitively binding with miR-200b/c/429 also promoted the progression of glioma by modulating CHD1 expression (23). Chai et al demonstrated that exosomal lncRNAe-ROR1-AS1 enhanced glioma progression by suppressing miR-4686 (24). LEF1-AS1 promoted glioma formation by competitively binding miR-489-3p to increase the expression of HIGD1A (25).…”

Section: The Functions and Mechanisms Of Lncrnas In Gliomasmentioning

confidence: 99%

Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment

2021

View full text Add to dashboard Cite

Accompanying the development of biomedicine, our knowledge of glioma, one of the most common primary intracranial carcinomas, is becoming more comprehensive. Unfortunately, patients with glioblastoma (GBM) still have a dismal prognosis and a high relapse rate, even with standard combination therapy, namely, surgical resection, postoperative radiotherapy and chemotherapy. The absence of validated biomarkers is responsible for the majority of these poor outcomes, and reliable therapeutic targets are indispensable for improving the prognosis of patients suffering from gliomas. Identification of both precise diagnostic and accurate prognostic markers and promising therapeutic targets has therefore attracted considerable attention from researchers. Encouragingly, accumulating evidence has demonstrated that long noncoding RNAs (lncRNAs) play important roles in the pathogenesis and oncogenesis of various categories of human tumors, including gliomas. Nevertheless, the underlying mechanisms by which lncRNAs regulate diverse biological behaviors of glioma cells, such as proliferation, invasion and migration, remain poorly understood. Consequently, this review builds on previous studies to further summarize the progress in the field of lncRNA regulation of gliomas over recent years and addresses the potential of lncRNAs as diagnostic and prognostic markers and therapeutic targets.

show abstract

“…LINC00470 in GDE could competitively bind to miR-580-3p in glioma cells to modify WEE1 expression and activate the PI3K/AKT/mTOR pathway, thus suppressing autophagy and strengthening the proliferation of glioma cells [ 23 ]. LncRNA ROR1-AS1 was upregulated in glioma tissues, and the high level of ROR1-AS1 predicted a poor prognosis [ 24 ]. Exosomal ROR1-AS1 induced the progression of glioma cell lines SHG-44 and U251 via harboring miR-4686, which could be a hopeful therapeutic target for glioma clinical treatment.…”

Section: Gde Ncrnas In Remodeling Glioma Behaviorsmentioning

confidence: 99%

“…Exosomal ROR1-AS1 induced the progression of glioma cell lines SHG-44 and U251 via harboring miR-4686, which could be a hopeful therapeutic target for glioma clinical treatment. Notably, lncRNA ROR1-AS1 was upregulated in GBM tissues and was associated with a poor prognosis in GBM patients [ 24 ]. Intriguingly, lncRNA ROR1-AS1 was encapsulated into tumor exosomes and then promoted SHG-44 and U251 glioma cell proliferation and progression via sponging the miR-4686 both in vitro and in vivo [ 24 ].…”

Section: Gde Ncrnas In Remodeling Glioma Behaviorsmentioning

confidence: 99%

Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance

Xiao

Zhang

et al. 2021

Cell Death Dis

View full text Add to dashboard Cite

Glioma is the most common and fatal tumor of the central nervous system in humans. Despite advances in surgery, radiotherapy, and chemotherapeutic agents, glioma still has a poor prognosis. The tumor microenvironment (TME) of glioma is of highly complex heterogeneity, which relies on a network-based communication between glioma cells and other stromal cell types. Exosomes are the most common type of naturally occurring extracellular vesicles, ranging in size from 40 to 160 nm, and can serve as carriers for proteins, RNAs, and other biologically active molecules. Recent evidence has shown that glioma-derived exosomes (GDEs) can be integrally detected in the local tissue and circulatory blood samples, and also can be transferred to recipient cells to mediate transmission of genetic information. Non-coding RNAs (ncRNAs) mainly including microRNA, long non-coding RNA, and circular RNA, account for a large portion of the human transcriptome. A broad range of ncRNAs encapsulated in GDEs is reported to exert regulatory functions in various pathophysiological processes of glioma. Herein, this review summarizes the latest findings on the fundamental roles of GDE ncRNAs that have been implicated in glioma behaviors, immunological regulation, diagnosis potential, and treatment resistance, as well as the current limitations and perspectives. Undoubtedly, a thorough understanding of this area will provide comprehensive insights into GDE-based clinical applications for combating gliomas.

show abstract

<p>Exosomal lncRNA ROR1-AS1 Derived from Tumor Cells Promotes Glioma Progression via Regulating miR-4686</p>

Cited by 29 publications

References 30 publications

Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma

Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma

Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment

Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance

Contact Info

Product

Resources

About